230 related articles for article (PubMed ID: 37064027)
1. Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practice.
de Biase D; Maloberti T; Corradini AG; Rosini F; Grillini M; Ruscelli M; Coluccelli S; Altimari A; Gruppioni E; Sanza V; Turchetti D; Galuppi A; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; De Leo A
Front Med (Lausanne); 2023; 10():1146499. PubMed ID: 37064027
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of Pathologic Features in Molecular Subgroups of Endometrial Carcinoma.
Ruscelli M; Maloberti T; Corradini AG; Rosini F; Querzoli G; Grillini M; Altimari A; Gruppioni E; Sanza V; Costantino A; Ciudino R; Errani M; Papapietro A; Coluccelli S; Turchetti D; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; D'Angelo E; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; de Biase D; De Leo A
J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240893
[TBL] [Abstract][Full Text] [Related]
3. A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer.
Betella I; Fumagalli C; Rafaniello Raviele P; Schivardi G; De Vitis LA; Achilarre MT; Aloisi A; Garbi A; Maruccio M; Zanagnolo V; Aletti G; Guerini-Rocco E; Mariani A; Maggioni A; Barberis M; Colombo N; Multinu F
Int J Gynecol Cancer; 2022 Jun; ():. PubMed ID: 35732351
[TBL] [Abstract][Full Text] [Related]
4. Assessing the New 2020 ESGO/ESTRO/ESP Endometrial Cancer Risk Molecular Categorization System for Predicting Survival and Recurrence.
Ouh YT; Oh Y; Joo J; Woo JH; Han HJ; Cho HW; Lee JK; Chun Y; Lim MN; Hong JH
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473326
[TBL] [Abstract][Full Text] [Related]
5. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
[TBL] [Abstract][Full Text] [Related]
6. Abnormal preoperative haematological parameters in Endometrial cancer; reflecting tumour aggressiveness or reduced response to radiotherapy?
Vrede SW; Donkers H; Reijnen C; Smits A; Visser NCM; Geomini PM; Ngo H; van Hamont D; Pijlman BM; Vos MC; Snijders MPLM; Kruitwagen R; Bekkers RLM; Galaal K; Pijnenborg JMA
J Obstet Gynaecol; 2024 Dec; 44(1):2294332. PubMed ID: 38186008
[TBL] [Abstract][Full Text] [Related]
7. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
[TBL] [Abstract][Full Text] [Related]
8. Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort.
Knez J; Sobocan M; Belak U; Kavalar R; Zupin M; Büdefeld T; Potocnik U; Takac I
Radiol Oncol; 2021 Sep; 56(1):76-82. PubMed ID: 34529911
[TBL] [Abstract][Full Text] [Related]
9. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T
Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303
[TBL] [Abstract][Full Text] [Related]
10. Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification.
Perrone E; Capasso I; De Felice F; Giannarelli D; Dinoi G; Petrecca A; Palmieri L; Foresta A; Nero C; Arciuolo D; Lorusso D; Zannoni GF; Scambia G; Fanfani F
Eur J Cancer; 2023 Jun; 186():98-112. PubMed ID: 37062213
[TBL] [Abstract][Full Text] [Related]
11. Endometrial Cancer: Transitioning from Histology to Genomics.
Mitric C; Bernardini MQ
Curr Oncol; 2022 Jan; 29(2):741-757. PubMed ID: 35200562
[TBL] [Abstract][Full Text] [Related]
12. Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features.
Kang EY; Wiebe NJ; Aubrey C; Lee CH; Anglesio MS; Tilley D; Ghatage P; Nelson GS; Lee S; Köbel M
J Pathol Clin Res; 2022 Jan; 8(1):19-32. PubMed ID: 34596362
[TBL] [Abstract][Full Text] [Related]
13. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic vs. Molecular Integrated Prognostication of Endometrial Carcinoma by European Guidelines.
Loukovaara M; Pasanen A; Bützow R
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158919
[TBL] [Abstract][Full Text] [Related]
15.
De Leo A; de Biase D; Lenzi J; Barbero G; Turchetti D; Grillini M; Ravegnini G; Angelini S; Zamagni C; Coluccelli S; Dondi G; De Iaco P; Perrone AM; Tallini G; Santini D; Ceccarelli C
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668727
[TBL] [Abstract][Full Text] [Related]
16. Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study.
Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
Gynecol Oncol; 2023 Mar; 170():210-220. PubMed ID: 36709662
[TBL] [Abstract][Full Text] [Related]
17. Application of novel algorithm on a retrospective series to implement the molecular classification for endometrial cancer.
Arcieri M; Vizzielli G; Occhiali T; Giorgiutti C; Tius V; Pregnolato S; Mariuzzi L; Orsaria M; Tulisso A; Damante G; D'Elia AV; Cucinella G; Chiantera V; Fanfani F; Ercoli A; Driul L; Scambia G; Restaino S
Eur J Surg Oncol; 2024 May; 50(7):108436. PubMed ID: 38820923
[TBL] [Abstract][Full Text] [Related]
18. Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
Nero C; Pasciuto T; Cappuccio S; Corrado G; Pelligra S; Zannoni GF; Santoro A; Piermattei A; Minucci A; Lorusso D; Fanfani F; Scambia G
Cancer; 2022 Aug; 128(15):2898-2907. PubMed ID: 35617463
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer.
Siegenthaler F; Epstein E; Büchi CA; Gmür A; Saner FACM; Rau TT; Carlson JW; Mueller MD; Imboden S
Int J Gynecol Cancer; 2023 Nov; 33(11):1702-1707. PubMed ID: 37666529
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
